Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

March 22, 2021March 22, 2021

Bacterial Fatty Acids May Play Role in Exacerbations in CF Children

News

Due to persistent bacterial infections, long-chain fatty acids (LCFA) are linked to continued inflammation in cystic fibrosis (CF) patients — and may contribute to pulmonary exacerbations in children with CF, ... Read more

March 17, 2021March 17, 2021

Phase 2b Trial of MS1819, Yeast-based EPI for CF, Fully Enrolled

News

AzurRx BioPharma announced that its Phase 2b trial evaluating the safety and efficacy of MS1819 in treating exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients is fully enrolled. Thirty adults ... Read more

February 12, 2021February 12, 2021

Organoids Accepted as Means to Targeted Therapy, Survey Reveals

cystic fibrosis, News

A recent survey shows that people with cystic fibrosis (CF) broadly favor targeted therapy using patient-derived organoids — the three-dimensional organ-like structures made from a patient’s own cells. The finding ... Read more

January 27, 2021January 27, 2021

COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say

News, syndicated

The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to ... Read more

January 25, 2021January 25, 2021

Minorities in US Ineligible for CFTR Modulators Due to Poorly Studied Mutations

cystic fibrosis, News

Individuals with cystic fibrosis (CF) from racial and ethnic minority groups in the U.S. are twice as likely to be ineligible for disease-modifying therapies than white patients, because their mutations ... Read more

January 20, 2021January 20, 2021

Compounds Raise Kalydeco’s Efficacy, May Be Future Combo Therapy

cystic fibrosis, News

Researchers boosted the activity of the cystic fibrosis transmembrane regulator (CFTR), the faulty protein at the heart of cystic fibrosis (CF), by altering the levels of a molecule called cyclic ... Read more

December 14, 2020December 14, 2020

CF Foundation Awards $2.76M to Research Differing COVID-19 Effects on Patients

cystic fibrosis, News

The Cystic Fibrosis Foundation (CFF) has awarded $2.76 million to fund 11 laboratory studies exploring the effects of COVID-19 on people with cystic fibrosis (CF). The hope is that a ... Read more

December 9, 2020December 9, 2020

Icenticaftor Effective in CF Patients With Certain Mutations, Phase 1/2 Trial Shows

News

Experimental therapy icenticaftor (QBW251) was able to improve lung function in cystic fibrosis (CF) patients carrying class 3 and 4 mutations in the CFTR gene, results from a Phase 1/2 ... Read more

December 4, 2020December 4, 2020

Vertex Donates $50k to Claire’s Place Foundation’s Work Proudly Program

News

Vertex Pharmaceuticals has awarded a $50,000 grant to Claire’s Place Foundation to support its Work Proudly Program, which helps adults with cystic fibrosis (CF) and caregivers with work-from-home opportunities. “We ... Read more

November 30, 2020November 30, 2020

Music May Make Airway Clearance Sessions More Enjoyable for Children

cystic fibrosis, News

Music composed especially for children with cystic fibrosis (CF) made airway clearance therapy a more enjoyable task, suggesting that it can help with treatment adherence and potentially lower costs related to ... Read more

Join our email list!